Advertisement

Position Statements

Expert Panel Recommendations

The National Lipid Association strives to champion issues of Clinical Lipidology for its members and for practitioners in the United States and internationally. In this role, the NLA has authored and endorsed various expert statements on issues affecting Lipidology. The following documents are evidence-based statements representing the pertinent issues for the practice of lipid management in clinical medicine.

Read More ...

Position Statements

On May 7, the decision was made to halt a late-stage trial of dalcetrapib, an experimental cholesterol drug intended to boost high density lipoprotein-cholesterol (HDL-C). A late-stage study, the dal-OUTCOMES Phase III trial, showed that dalcetrapib was not working effectively. The link above provides the joint response from the European Atherosclerosis Society (EAS), International Atherosclerosis Society (IAS) and the National Lipid Association (NLA).

Read More ...

0
No votes yet
Publish Date: 
Wednesday, August 1, 2012 - 12:00

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service